TLDR DPCP treatment for alopecia areata can sometimes cause vitiligo.
The document reported a case of a 30-year-old Brazilian male who developed vitiligo after undergoing diphencyprone (DPCP) therapy for alopecia areata. DPCP, a contact sensitizer used since the 1970s, has been effective in treating alopecia areata but can cause side effects, including rare cases of vitiligo. The patient experienced complete hair regrowth but developed hypopigmented lesions, which were confirmed to be vitiligo through a patch test. The study highlighted the need to inform patients about the potential risk of vitiligo, especially those with a personal or familial history of the condition.
47 citations,
September 1995 in “British Journal of Dermatology” Diphencyprone therapy for hair loss can cause vitiligo.
55 citations,
January 1988 in “Dermatology” Diphencyprone treatment for alopecia areata can cause vitiligo in some patients.
15 citations,
June 2015 in “F1000Research” Psoriasis may be chronic because it lacks certain immune system controls that prevent overreaction.
23 citations,
July 2008 in “British journal of dermatology/British journal of dermatology, Supplement” Topical contact sensitizers can treat certain skin conditions but are rarely used in the U.K.
11 citations,
May 2009 in “Actas Dermo-Sifiliográficas” Some treatments can help hair regrowth in alopecia areata, but none offer a cure, and effectiveness varies.
4 citations,
September 2011 in “Expert Review of Dermatology” Various treatments exist for alopecia areata, but none are completely satisfactory; choice depends on age, disease extent, and preference.
September 2022 in “Dermatology and therapy” Contact immunotherapy might help treat various skin conditions, but more research is needed to confirm its safety and effectiveness.
